60
Participants
Start Date
February 28, 2025
Primary Completion Date
February 28, 2026
Study Completion Date
December 31, 2026
Efgartigimod + Telitacicept (1-week interval) group
"Drug 1: Efgartigimod~Generic Name: Efgartigimod Formulation: Injection (Intravenous) Dose: 10 mg/kg Frequency: Once a week Route of Administration: Intravenous infusion Duration: 4 weeks (Week 0 to Week 4) Drug 2: Telitacicept~Generic Name: Telitacicept Formulation: Injection (Subcutaneous) Dose: 240 mg Frequency: Once a week Route of Administration: Subcutaneous injection Duration: 25 weeks (Week 5 to Week 29)"
Efgartigimod + Telitacicept (2-week interval) group
"Drug 1: Efgartigimod~Generic Name: Efgartigimod Formulation: Injection (Intravenous) Dose: 10 mg/kg Frequency: Once a week Route of Administration: Intravenous infusion Duration: 4 weeks (Week 0 to Week 4) Drug 2: Telitacicept~Generic Name: Telitacicept Formulation: Injection (Subcutaneous) Dose: 240 mg Frequency: Once a week Route of Administration: Subcutaneous injection Duration: 24 weeks (Week 6 to Week 29)"
Telitacicept-only group
Drug: Telitacicept Generic Name: Telitacicept Formulation: Injection (Subcutaneous) Dose: 240 mg Frequency: Once a week Route of Administration: Subcutaneous injection Duration: 30 weeks (Week 0 to Week 29)
Zhejiang Provincial People's Hospital
OTHER
Sir Run Run Shaw Hospital
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Ningbo Medical Center Lihuili Hospital
OTHER_GOV
First Affiliated Hospital of Wenzhou Medical University
OTHER